Clinical trials: Mesenchymal Stromal Cells
Defect of Articular Cartilage, Cartilage Injury
Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair
This is a proof-of-concept study to determine the safety and efficacy of a novel device to increase the reparative capacity of the knee.
- Conditions
- Defect of Articular Cartilage, Cartilage Injury, Osteoarthritis, Knee
- Trial name
- AURA (NCT02696876)
- Testing
- Arthroscopic synovial brushing, Microfracture
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Leeds
Corona Virus Infection, ARDS
Use of UC-MSCs for COVID-19 Patients
The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute…
- Conditions
- Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome
- Trial name
- NCT04355728
- Testing
- Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Camillo Ricordi
Uremia
Effect of SVF Derived MSC in DCD Renal Transplantation
The objective of this trial is to determine if autologous Stromal Vascular Fraction (SVF) derived Mesenchymal Stem Cell (MSC) infusion during and after kidney transplantation from Donation after Citizen Death (DCD) can…
- Trial name
- NCT02492490
- Testing
- SVFderived MSC transplantations, Basiliximab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fuzhou General Hospital
Premature Ovarian Insufficiency
Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
- Trial name
- NCT07775391
- Testing
- hUC-MSCs Injection (Phase I), hUC-MSCs Injection (Phase IIa)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Chronic Graft-Versus-Host Disease
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged.
- Trial name
- MSC-cGvHD (NCT02291770)
- Testing
- Mesenchymal Stromal Cells
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Guangdong Provincial People's Hospital
Graft-Versus-Host Disease
Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
Background: Sometimes after stem cells are transplanted, donor cells attack the recipient s cells and cause tissue damage. This is called acute graft-versus-host-disease (GVHD).
- Trial name
- NCT02379442
- Testing
- MSC
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 2
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells.
- Trial name
- NCT04126603
- Testing
- Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sabyasachi Sen